Orthocell Ltd

Orthocell is a regenerative medicine company with a focus on biotechnology based in Australia. Established in 2008, the company is dedicated to developing breakthrough products that harness the power of the human body to heal, aiming to restore mobility, function, and performance. Orthocell's product portfolio comprises two complementary platform products - a collagen medical device and autologous cell therapies. The CelGro™ platform of collagen medical devices is specifically designed to augment the surgical repair of bone, nerve, tendon, and cartilage. On the other hand, the company's cell therapies encompass autologous tendon therapy and autologous chondrocyte implantation (OrthoACI™), aiming to facilitate the regeneration of damaged tendon and cartilage tissue. Though specific details regarding the company's last investment remain undisclosed, it is clear that Orthocell presents an intriguing proposition within the regenerative medicine space. As a venture capital entity, monitoring the company's advancements and potential opportunities for collaboration could prove to be valuable in staying abreast of innovative developments within the biotechnology sphere. Keep an eye on Orthocell (ASX:OCC) for further insights and investment prospects.